|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Egan A, Dong Y, Zhang H, Qi Y, Balk SP and
Sartor O: Castration-resistant prostate cancer: Adaptive responses
in the androgen axis. Cancer Treat Rev. 40:426–433. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang X, Tang J, Zhi X, Xie K, Wang W, Li
Z, Zhu Y, Yang L, Xu H and Xu Z: miR-874 functions as a tumor
suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway
in gastric cancer. Oncotarget. 6:1605–1617. 2015.PubMed/NCBI
|
|
9
|
Liu C, Kelnar K, Liu B, Chen X,
Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et
al: The microRNA miR-34a inhibits prostate cancer stem cells and
metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fu W, Tao T, Qi M, Wang L, Hu J, Li X,
Xing N, Du R and Han B: MicroRNA-132/212 upregulation inhibits
TGF-β-mediated epithelial-mesenchymal transition of prostate cancer
cells by targeting SOX4. Prostate. 76:1560–1570. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nishikawa R, Goto Y, Kojima S, Enokida H,
Chiyomaru T, Kinoshita T, Sakamoto S, Fuse M, Nakagawa M, Naya Y,
et al: Tumor-suppressive microRNA-29s inhibit cancer cell migration
and invasion via targeting LAMC1 in prostate cancer. Int J Oncol.
45:401–410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu X, Su B, Xie C, Wei S, Zhou Y, Liu H,
Dai W, Cheng P, Wang F, Xu X and Guo C: Sonic hedgehog-Gli1
signaling pathway regulates the epithelial mesenchymal transition
(EMT) by mediating a new target gene, S100A4, in pancreatic cancer
cells. PLoS One. 9:e964412014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takebe N, Harris PJ, Warren RQ and Ivy SP:
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog
pathways. Nat Rev Clin Oncol. 8:97–106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Clement V, Sanchez P, de Tribolet N,
Radovanovic I and Ruiz i Altaba A: HEDGEHOG-GLI1 signaling
regulates human glioma growth, cancer stem cell self-renewal, and
tumorigenicity. Curr Biol. 17:165–172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ahmed A, Ali S and Sarkar FH: Advances in
androgen receptor targeted therapy for prostate cancer. J Cell
Physiol. 229:271–276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brabletz T, Jung A, Spaderna S, Hlubek F
and Kirchner T: Opinion: Migrating cancer stem cells-an integrated
concept of malignant tumour progression. Nat Rev Cancer. 5:744–749.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deshmukh A, Deshpande K, Arfuso F,
Newsholme P and Dharmarajan A: Cancer stem cell metabolism: A
potential target for cancer therapy. Mol Cancer. 15:692016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Colak S and Medema JP: Cancer stem
cells-important players in tumor therapy resistance. FEBS J.
281:4779–4791. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dave B, Mittal V, Tan NM and Chang JC:
Epithelial-mesenchymal transition, cancer stem cells and treatment
resistance. Breast Cancer Res. 14:2022012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miska EA: How microRNAs control cell
division, differentiation and death. Curr Opin Genet Dev.
15:563–568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li X, Yu Z, Li Y, Liu S, Gao C, Hou X, Yao
R and Cui L: The tumor suppressor miR-124 inhibits cell
proliferation by targeting STAT3 and functions as a prognostic
marker for postoperative NSCLC patients. Int J Oncol. 46:798–808.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng Z, Ding M, Ni J, Song D, Huang J and
Wang J: MiR-142 acts as a tumor suppressor in osteosarcoma cell
lines by targeting Rac1. Oncol Rep. 33:1291–1299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou N, Fei D, Zong S, Zhang M and Yue Y:
MicroRNA-138 inhibits proliferation, migration and invasion through
targeting hTERT in cervical cancer. Oncol Lett. 12:3633–3639. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Davidson MR, Larsen JE, Yang IA, Hayward
NK, Clarke BE, Duhig EE, Passmore LH, Bowman RV and Fong KM:
MicroRNA-218 is deleted and downregulated in lung squamous cell
carcinoma. PLoS One. 5:e125602010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu H, Gao G, Jiang L, Guo L, Lin M, Jiao
X, Jia W and Huang J: Decreased expression of miR-218 is associated
with poor prognosis in patients with colorectal cancer. Int J Clin
Exp Pathol. 6:2904–2911. 2013.PubMed/NCBI
|
|
29
|
Guan H, Wei G, Wu J, Fang D, Liao Z, Xiao
H, Li M and Li Y: Down-regulation of miR-218-2 and its host gene
SLIT3 cooperate to promote invasion and progression of thyroid
cancer. J Clin Endocrinol Metab. 98:E1334–E1344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang XX, Ge SJ, Wang XL, Jiang LX, Sheng
MF and Ma JJ: miR-218 tissue expression level is associated with
aggressive progression of gastric cancer. Genet Mol Res.
15:2016.
|
|
31
|
Wang HT, Liu AG, Luo DS, Zhou ZN, Lin HG,
Chen RZ, He JS and Chen K: miR-218 expression in osteosarcoma
tissues and its effect on cell growth in osteosarcoma cells. Asian
Pac J Trop Med. 7:1000–1004. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang G, Fu Y, Liu G, Ye Y and Zhang X:
miR-218 inhibits proliferation, migration, and EMT of gastric
cancer cells by targeting WASF3. Oncol Res. 25:355–364. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang Z, Song Q, Zeng R, Li J, Li J, Lin
X, Chen X, Zhang J and Zheng Y: MicroRNA-218 inhibits EMT,
migration and invasion by targeting SFMBT1 and DCUN1D1 in cervical
cancer. Oncotarget. 7:45622–45636. 2016.PubMed/NCBI
|
|
34
|
Tu Y, Gao X, Li G, Fu H, Cui D, Liu H, Jin
W and Zhang Y: MicroRNA-218 inhibits glioma invasion, migration,
proliferation, and cancer stem-like cell self-renewal by targeting
the polycomb group gene Bmi1. Cancer Res. 73:6046–6055. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kogo R, How C, Chaudary N, Bruce J, Shi W,
Hill RP, Zahedi P, Yip KW and Liu FF: The microRNA-218~Survivin
axis regulates migration, invasion, and lymph node metastasis in
cervical cancer. Oncotarget. 6:1090–1100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheng Y, Yang X, Deng X, Zhang X, Li P,
Tao J and Lu Q: MicroRNA-218 inhibits bladder cancer cell
proliferation, migration, and invasion by targeting BMI-1. Tumour
Biol. 36:8015–8023. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li F, Gu C, Tian F, Jia Z, Meng Z, Ding Y
and Yang J: MiR-218 impedes IL-6-induced prostate cancer cell
proliferation and invasion via suppression of LGR4 expression.
Oncol Rep. 35:2859–2865. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Han G, Fan M and Zhang X: MicroRNA-218
inhibits prostate cancer cell growth and promotes apoptosis by
repressing TPD52 expression. Biochem Biophys Res Commun.
456:804–809. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru
T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya
Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell
migration and invasion via targeting of LASP1 in prostate cancer.
Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Inaguma S, Kasai K, Hashimoto M and Ikeda
H: GLI1 modulates EMT in pancreatic cancer-letter. Cancer Res.
72:3702–3703. 3704–3705. 2012. View Article : Google Scholar : PubMed/NCBI
|
